DiscoverWSJ What’s NewsWhy AstraZeneca-Oxford's Covid-19 Vaccine Is Different
Why AstraZeneca-Oxford's Covid-19 Vaccine Is Different

Why AstraZeneca-Oxford's Covid-19 Vaccine Is Different

Update: 2020-11-231
Share

Description

P.M. Edition for Nov. 23. AstraZeneca and the University of Oxford say their two-dose Covid-19 vaccine has proven to be up to 90% effective. But its efficacy varied widely depending on the dosage. Reporter Joe Walker discusses how this third Western-developed Covid-19 vaccine is different from others and could be more widely used globally. Plus, President-elect Joe Biden plans to tap former Federal Reserve Chair Janet Yellen as the next Treasury Secretary. Annmarie Fertoli hosts.

Learn more about your ad choices. Visit megaphone.fm/adchoices

Comments 
Download from Google Play
Download from App Store
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Why AstraZeneca-Oxford's Covid-19 Vaccine Is Different

Why AstraZeneca-Oxford's Covid-19 Vaccine Is Different

The Wall Street Journal